Iterum Therapeutics plc ITRM

Healthcare Biotechnology

Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. It is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase III clinical development with an oral formulation. Sulopenem is a potent, thiopenem antibiotic delivered intravenously, which is active against bacteria that belong to the group of organisms known as gram-negatives and causes urinary tract and intra-abdominal infections. It has also developed sulopenem in an oral tablet formulation, sulopenem etzadroxil-probenecid. Sulopenem also has an IV formulation. Sulopenem has demonstrated potent in vitro activity against a variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics.

NDAQ:ITRM - Post by User

Iterum Therapeutics plc

<< Previous

Bullboard Posts

Next >>

Post by wallpaper2on Jun 27, 2021 10:18am

185 Views

Post# 33457379

Telling after close purchase on Iterum.

Someone purchased 25000 shares at S2.23 at the close. Six million shares crossed earlier. Something very good happening? Three weeks of trading before FDA approval and multiple move in share price. This drug could be worth $30-$50 per share for Iterum.

<< Previous

Bullboard Posts

Next >>

Critical materials crisis: Diversifying away from China’s monopoly